NNovo Nordisk Read More Novo Nordisk’s triple agonist delivers up to 19.7% weight loss2026-02-26 Novo Nordisk’s triple agonist UBT251 delivered a mean weight loss of 19.7% after 24 weeks in a Phase…
NNovo Nordisk Read More Triple agonist UBT251 delivers up to 19.7%2026-02-24 UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed…